Antisense Therapeutics to Establish Level 1 American Depository Receipt Program

Antisense Therapeutics to Establish Level 1 American Depository
Receipt Program 


MELBOURNE, Australia, Oct. 7  /PRNewswire/ -- Antisense Therapeutics Limited
(ASX:ANP) announced that it has accepted a proposal from The Bank of New York
to establish a Level 1 American Depository Receipt (ADR) program.

The establishment of this ADR program will facilitate the purchase of Antisense
Therapeutics shares by United States investors.

This initiative is a logical extension of the Company's focus on its
international development, and an appropriate vehicle to leverage the high
awareness of and regard for antisense technology generally and the growing
international interest in Antisense Therapeutics' product development plans
specifically.

Mark Diamond, CEO of Antisense commented: "We are very excited to take this
initial step in bringing the Antisense story to international investors. A
vital part of our long-term strategy to enhance shareholder value is to improve
liquidity and broaden and diversify our shareholder base by enhancing the
Company's visibility in the world's largest capital market.  The ADR program
will help us capitalize on landmark achievements by making investing easier for
existing and potential US investors."

About ADRs

ADRs are commonly used to facilitate US investors investing in foreign
companies not listed in the USA.  An ADR is created when a broker purchases a
company's shares on the home stock market and delivers those to the
depositary's local custodian bank, which then instructs the depositary bank,
The Bank of New York, to issue Depositary Receipts.  Depositary receipts may
trade freely, just like any other security, in the over-the-counter (OTC)
market.

About Antisense Therapeutics Limited

Antisense Therapeutics Limited (ASX:ANP) is an Australian publicly listed
biopharmaceutical drug discovery and development company.  ANP's mission is to
create, develop and commercialise novel antisense pharmaceuticals for large
unmet markets.  Its two most advanced projects target Multiple Sclerosis
(ATL1102), and Psoriasis (ATL1101).

ANP plans to commercialise its pipeline via licensing/collaboration agreements
with major biotechnology and pharmaceutical companies.

ANP's major shareholders include Circadian Technologies Limited (ASX:CIR), Isis
Pharmaceuticals Inc (NASDAQ:ISIS) and Queensland Investment Corporation. 

DATASOURCE: Antisense Therapeutics Limited



CONTACT:  Mark Diamond, Managing Director, [phone], or Natalie

Korchev, Company Secretary, [phone], both of Antisense Therapeutics

Limited; or Rachel Levine of The Anne McBride Co., [phone], ext. 207,

for Antisense Therapeutics Limited



Web site: http://www.antisense.com.au/

Copyright